期刊
NATURE MEDICINE
卷 26, 期 7, 页码 1044-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0932-2
关键词
-
资金
- Canadian Institute of Health Research (CIHR) Vanier Scholarship
- AANS/CNS Section on Tumors & NREF Research Fellowship Grant
- Hold'em for Life Oncology Fellowship
- CIHR Banting Fellowship
- National Institutes of Health [R01NS102669]
- CIHR [159452, PJT 165986]
- Brain Tumor Charity UK Quest for Cures grant [GN-000430]
- CIHR New Investigator salary award [201512MSH360794-228629]
- Helen M. Cooke professorship from Princess Margaret Cancer Foundation
- Gattuso-Slaight Personalized Cancer Medicine Fund from Princess Margaret Cancer Foundation
- Canada Research Chair
- CIHR Foundation grant [FDN 148430]
- NSERC [489073]
- Ontario Institute for Cancer Research
- province of Ontario
- [P50CA221747]
- NATIONAL CANCER INSTITUTE [ZIABC011847, ZIABC011846, ZIABC011850] Funding Source: NIH RePORTER
A cell-free DNA-methylation sequencing assay accurately identifies different brain tumor types using plasma samples. Definitive diagnosis of intracranial tumors relies on tissue specimens obtained by invasive surgery. Noninvasive diagnostic approaches provide an opportunity to avoid surgery and mitigate unnecessary risk to patients. In the present study, we show that DNA-methylation profiles from plasma reveal highly specific signatures to detect and accurately discriminate common primary intracranial tumors that share cell-of-origin lineages and can be challenging to distinguish using standard-of-care imaging.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据